Thank you very much, Mr. Chair.
I join my colleagues in thanking the witnesses for being with us today.
We all have women around us to whom we can send energy and dedicate the important work we do here in this committee.
Dr. Hanley, your main focus is on ovarian cancer prevention, as you clearly explained in your opening remarks, particularly through salpingectomy, surgery that involves removing one or both fallopian tubes. You also talked about contraception and healthy pregnancies.
The brief that Ovarian Cancer Canada submitted to the committee indicates that the treatments available for ovarian cancer have unfortunately not changed significantly since the 1990s, and that the survival rate for ovarian cancer hasn't improved in 50 years. That's a sad statement.
Can you explain the underlying reasons for the lack of progress in ovarian cancer treatments and the lack of improvement in survival rates?